ReviewNanoscale2016
Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy.
Review in Nanoscale, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma.Lung cancer (Amsterdam, Netherlands) · 2026Article
- Recovery of IR700 Fluorescence After Near-Infrared Photoimmunotherapy: Discovery and Mechanistic Insights.Cancers · 2026Article
- Enhancement of drug delivery through fibroblast activation protein-targeted near-infrared photoimmunotherapy.JCI insight · 2025Article
- Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Next-Generation Cancer Treatment: Photoimmunotherapy's Promise for Unresectable Head and Neck Cancers.Pharmaceutics · 2025Review
- Unleashing the Potential of Metal Ions in cGAS-STING Activation: Advancing Nanomaterial-Based Tumor Immunotherapy.ACS omega · 2025Review
- Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.Antibody therapeutics · 2025Review
- Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- PD-L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self-Delivery.Advanced healthcare materials · 2024Article
- Article
- Photodynamic therapy with paclitaxel-encapsulated indocyanine green-modified liposomes for breast cancer.Frontiers in oncology · 2024Article
- Progress of near-infrared-II fluorescence in precision diagnosis and treatment of colorectal cancer.Heliyon · 2023Review
- Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells.Molecules (Basel, Switzerland) · 2023Article
- In vivo imaging of acute physiological responses after treatment of cancer with near-infrared photoimmunotherapy.Molecular imaging and biology · 2023Article
- Biomimetic nanoparticles targeting atherosclerosis for diagnosis and therapy.Smart medicine · 2023Review
- In Vitro Comparative Study of Near-Infrared Photoimmunotherapy and Photodynamic Therapy.Cancers · 2023Article
- The development of live microorganism-based oxygen shuttles for enhanced hypoxic tumor therapy.Materials today. Bio · 2023Review
- Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts.Molecular cancer therapeutics · 2023Article
- Visualizing vasculature and its response to therapy in the tumor microenvironment.Theranostics · 2023Review
- Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
To date, the delivery of nano-sized therapeutic agents to cancers largely relies on enhanced permeability and retention (EPR) effects that are caused by the leaky nature of cancer vasculature. However, nano-sized agents delivered in this way have demonstrated limited success in oncology due to the relatively small magnitude of the EPR effect. For achieving superior delivery of nano-sized agents, super-enhanced permeability and retention (SUPR) effects are needed. Near infrared photo-immunotherapy (NIR-PIT) is a recently reported therapy that treats tumors with light therapy and subsequently causes an increase in nano-drug delivery up to 24-fold compared with untreated tumors in which only the EPR effect is present. SUPR effects could enhance delivery into tumor beds of a wide variety of nano-sized agents including particles, antibodies, and protein binding small molecular agents. Therefore, taking advantage of the SUPR effects after NIR-PIT may be a promising avenue to utilize a wide variety of nano-drugs in a highly effective manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.